MetLife Investment Management’s Minerva Neurosciences NERV Stock Holding History

MetLife Investment Management’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,945	Closed	-$121K	–	2318
2019 Q3	$121K	Sell	1,945 -93	-5%	-$5.27K	﹤0.01%	2224
2019 Q2	$91.8K	Hold	2,038	–	–	﹤0.01%	2385
2019 Q1	$128K	Hold	2,038	–	–	﹤0.01%	2214
2018 Q4	$110K	Hold	2,038	–	–	﹤0.01%	2255
2018 Q3	$205K	Hold	2,038	–	–	﹤0.01%	2065
2018 Q2	$135K	Buy	+2,038	New	+$124K	﹤0.01%	2113

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

IVAI

Index Venture Associates IV St. Helier, Channel Islands, Jersey $6.24M AUM

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

MetLife Investment Management's NERV Position: Q4 2019 in Review

MetLife Investment Management sold out of Minerva Neurosciences (NERV) in Q4 2019, closing a stake of 1,945 shares — an estimated $121K sold.

MetLife Investment Management first reported a position in NERV in Q2 2018 and held it in 6 quarters. The position peaked at $205K in Q3 2018. 92 funds tracked by Wall St. Rank hold NERV as of Q4 2019.

MetLife Investment Management reported no remaining Minerva Neurosciences position as of Q4 2019 after selling out during the quarter.
MetLife Investment Management sold 1,945 Minerva Neurosciences shares in Q4 2019, an estimated $121K.
MetLife Investment Management first reported a position in Minerva Neurosciences in Q2 2018 and held it in 6 quarters.
MetLife Investment Management's Minerva Neurosciences position peaked at $205K in Q3 2018.
92 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2019.

Based on MetLife Investment Management's 13F filing for Q4 2019, filed 14 Feb 2020.